APOB and metabolic syndrome: We previously demonstrated that apoB levels calculated by our novel equation were similar to directly-measured apoB levels, not only for the whole Korean study population, but also for clinically relevant subgroups, including patients with diabetes, atherogenic dyslipidemia, and those being treated with lipid-lowering agents, regardless of their serum triglyceride levels [4].